Preferred Label : Anti-EGFR/anti-HER3 Antibody-drug Conjugate BL-B01D1;
NCIt synonyms : ADC BL-B01D1; Dual Target ADC BL-B01D1; Anti-EGFR/HER3 ADC BL-B01D1; Anti-EGFR/anti-HER3 ADC BL-B01D1; Dual Antibody ADC BL-B01D1;
NCIt definition : A dual-targeted antibody-drug conjugate (ADC) consisting of a monoclonal antibody
directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the
epidermal growth factor receptor 3 (HER3; ErbB3) and conjugated to an as of yet not
elucidated cytotoxic payload, with potential antineoplastic activity. Upon administration
of anti-EGFR/anti-HER3 ADC BL-B01D1, the monoclonal antibody moieties simultaneously
target and bind to EGFR and HER3 expressed on cancer cells. Following receptor internalization,
the cytotoxic moiety is released and kills EGFR/HER3-expressing tumor cells through
an as of yet unknown mechanism of action (MoA). EGFR and HER3, both upregulated and/or
mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.
Simultaneously targeting both EGFR and HER3 may enhance the anti-tumor activity of
BL-B01D1.;
Molecule name : BL B01D1; BL-B01D1;
NCI Metathesaurus CUI : CL1779171;
Origin ID : C186670;
UMLS CUI : C5667079;
Semantic type(s)
- concept_is_in_subset
- has_target
